Literature DB >> 33536242

BLISS in the Treatment of Lupus Nephritis.

Joshua M Thurman1.   

Abstract

Entities:  

Keywords:  B cell; biologic; lupus nephritis

Mesh：

Substances：

Year:  2021        PMID： 33536242      PMCID： PMC8216619          DOI： 10.2215/CJN.17991120

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  10 in total

1.  Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.

Authors:  David Wofsy; Jan L Hillson; Betty Diamond
Journal:  Arthritis Rheum       Date:  2012-11

2.  A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Authors:  Brad H Rovin; Neil Solomons; William F Pendergraft; Mary Anne Dooley; James Tumlin; Juanita Romero-Diaz; Lidia Lysenko; Sandra V Navarra; Robert B Huizinga
Journal:  Kidney Int       Date:  2018-11-09       Impact factor: 10.612

3.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors:  Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2011-12

4.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

5.  Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.

Authors:  Maria Dall'Era; Miriam G Cisternas; Dawn E Smilek; Laura Straub; Frédéric A Houssiau; Ricard Cervera; Brad H Rovin; Meggan Mackay
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

6.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Authors:  Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

7.  Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

Authors:  Liliana Michelle Gomez Mendez; Matthew D Cascino; Jay Garg; Tamiko R Katsumoto; Paul Brakeman; Maria Dall'Era; Richard John Looney; Brad Rovin; Leonard Dragone; Paul Brunetta
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-08       Impact factor: 8.237

8.  Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Authors:  Ellen M Ginzler; Stephen Wax; Anand Rajeswaran; Samuel Copt; Jan Hillson; Eleanor Ramos; Nora G Singer
Journal:  Arthritis Res Ther       Date:  2012-02-07       Impact factor: 5.156

9.  Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice.

Authors:  Daisuke Kawabata; Jeganathan Venkatesh; Meera Ramanujam; Anne Davidson; Christine M Grimaldi; Betty Diamond
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

10.  Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.

Authors:  Yemil Atisha-Fregoso; Susan Malkiel; Kristina M Harris; Margie Byron; Linna Ding; Sai Kanaparthi; William T Barry; Wendy Gao; Kristin Ryker; Patti Tosta; Anca D Askanase; Susan A Boackle; W Winn Chatham; Diane L Kamen; David R Karp; Kyriakos A Kirou; S Sam Lim; Bradley Marder; Maureen McMahon; Samir V Parikh; William F Pendergraft; Amber S Podoll; Amit Saxena; David Wofsy; Betty Diamond; Dawn E Smilek; Cynthia Aranow; Maria Dall'Era
Journal:  Arthritis Rheumatol       Date:  2020-12-01       Impact factor: 15.483
  10 in total
  1 in total

1.  The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane.

Authors:  Beatriz Teresita Martín-Márquez; Minoru Satoh; Rogelio Hernández-Pando; Erika Aurora Martínez-García; Marcelo Heron Petri; Flavio Sandoval-García; Oscar Pizano-Martinez; Trinidad García-Iglesias; Fernanda Isadora Corona-Meraz; Monica Vázquez-Del Mercado
Journal:  PLoS One       Date:  2021-10-27       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.